Craving and relapse reduction in methamphetamine-dependent patients.
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will be treated with a daily dose of 100 mg amantadine capsules (Hakim, Iran) that will be increased by 100 mg every week to achieve the maxi
if tolerated by the patients. The matrix program will be performed for two months with the latest dose and by the end of the program, the medication will be ce
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 18-60 years old patients The participants who meet the criteria of methamphetamine use disorder based on DSM-V Only depend on methamphetamine Patients' satisfaction for participation in the study
Exclusion criteria
Exclusion criteria: Psychiatric drugs administration The concurrent major psychiatric disorders such as mood and thinking disorders Major and chronic physical disorders Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amantadine add-on therapy effects on craving and relapse reduction among patients with methamphetamine dependence. Timepoint: Methamphetamine urine test will be done weekly during the intervention and monthly in follow-up period. Method of measurement: CCQ-Brief Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anxiety. Timepoint: Before and 2 months after the Intervention. Method of measurement: Hospital Anxiety - Depressive Scale.;Depression. Timepoint: Before and 2 months after the Intervention. Method of measurement: Hospital Anxiety - Depressive Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGholam Reza Kheirabadi
Esfahan University of Medical Sciences
Outcome results
None listed